Metformin Use May Curb BCC Risk, Study
Metformin has anticarcinogenic properties and is also known to inhibit the sonic hedgehog pathway, but population-based studies analyzing the potential protective effect for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are needed.

This study aimed to delineate the association between metformin use and invasive SCC, SCC in situ (SCCis), and BCC.

A population-based case-control study design was employed using all 6880 patients diagnosed with first-time BCC, SCCis, or invasive SCC, and 69,620 population controls. Multivariate odds ratios (ORs) were calculated using conditional logistic regression.

-- Metformin was associated with a lower risk of developing BCC, even at low doses.

-- No increased risk of developing SCC was observed. SCCis risk was mildly elevated in the 501-1500 daily dose unit category.

Conclusively, Metformin is associated with decreased risk of BCC development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies.